Perfil
Hani N.
Sabbah is the founder of G3 Pharmaceuticals, Inc. He is currently working as a Director at MateraCor, Inc.
Cargos activos de Hani N. Sabbah
| Empresas | Cargo | Inicio |
|---|---|---|
MateraCor, Inc.
 MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Hani N. Sabbah.
| Empresas | Cargo | Fin |
|---|---|---|
G3 Pharmaceuticals, Inc.
 G3 Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology G3 Pharmaceuticals, Inc. is a development-stage biopharmaceutical company. It manufactures and develops galectin-3 biology, cardiovascular pharmaceutical and carbohydrate drugs. The company is headquartered in Lexington, MA. | Fundador | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
G3 Pharmaceuticals, Inc.
G3 Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology G3 Pharmaceuticals, Inc. is a development-stage biopharmaceutical company. It manufactures and develops galectin-3 biology, cardiovascular pharmaceutical and carbohydrate drugs. The company is headquartered in Lexington, MA. | Health Technology |
MateraCor, Inc.
MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Health Technology |
- Bolsa de valores
- Insiders
- Hani N. Sabbah
